New Launch2 Jul 2025, 05:01 pm
Aurobindo Pharma Subsidiary Receives Marketing Approval for Trastuzumab Biosimilar Dazublys in Europe
AI Summary
Aurobindo Pharma Ltd. announced that its wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o, received marketing authorization from the European Commission for its trastuzumab biosimilar version, Dazublys™. This marks CuraTeQ's third biosimilar approval by the EMA, following Dyrupeg™ in April 2025 and Zefylti™ in February 2025, making it the fourth biosimilar approval in the EU, including Bevgolva™ approved by the UK's MHRA in December 2024.
Key Highlights
- Aurobindo Pharma subsidiary CuraTeQ Biologics s.r.o receives marketing approval for trastuzumab biosimilar Dazublys from European Commission.
- Dazublys™ is the third biosimilar approved by EMA for CuraTeQ, following Dyrupeg™ in April 2025 and Zefylti™ in February 2025.
- This marks the fourth biosimilar approval in the EU for Aurobindo Pharma, including Bevgolva™ approved by the UK's MHRA in December 2024.
- Trastuzumab biosimilar Dazublys™ aims to provide an affordable alternative to the original biological drug.
- Aurobindo Pharma continues to expand its presence in the global biosimilars market.